The predictive value of procalcitonin for postoperative early pancreatic fistula

Quanyu Zhou¹, Yuxiao Xia² and Zehua Lei*¹

Abstract
Background: To investigate the early prediction value of procalcitonin (PCT) in pancreatic fistula (POPF) after pancreateoduodenectomy (PD).
Method: Retrospective analysis of clinical data of 67 patients undergoing pancreateoduodenectomy (PD) and 19 patients undergoing distal pancreatectomy (DP) were performed in the Department of Hepatobiliary Surgery, Leshan People’s Hospital from January 2017 to December 2018. All patients were divided into POPF group and non-POPF group depending on the presence of pancreatic fistula. And fistulas were classified according to the ISGPF classification scheme. Plasma PCT levels, serum CRP concentration, and WBC counts were assessed preoperatively and on postoperative days (PODs) 1, 3, and 5. Statistical analyses were performed with statistical software. The ROC curve was used to analyze the efficacy of PCT and CRP in POPF prediction after surgery and determine their Cut-off value.
Result: There were no statistically significant differences identified in age, gender, BMI, diabetes, abdominal surgery history, preoperative laboratory data, operation time, intraoperative bleeding volume, tumor nature and medical expenses of PD patients between the two groups (P > 0.05). While the incidence of postoperative hyperglycemia, postoperative ICU rate and postoperative hospital stay were statistically significant (P < 0.05). The AUC for PCT diagnosis of pancreatic fistula 1 day after surgery was 0.77 (95% CI: 0.675 ~ 0.860). Compared with CRP [0.53 (95% CI: 0.420 ~ 0.639)] and WBC [0.60 (95% CI: 0.490 ~ 0.705)], the optimal cut-off value (cut-off) was 0.67 μg/L. At this time, the sensitivity and specificity of detecting pancreatic fistula were 73.68 and 76.12%, respectively. The results at 3 days after surgery were similar to those at 5 days after surgery. And DP patients had similar results as PD patients.
Conclusion: The PCT is valuable for early prediction of pancreatic fistula after Pancreatectoduodenectomy.
Keywords: Pancreatectoduodenectomy, Postoperative pancreatic fistula, Procalcitonin

Background
Pancreatectoduodenectomy (PD) is the only curative treatment of malignant diseases of the periampullary region of the pancreas and is also recommended for the treatment of premalignant tumors at a high risk of degeneration. In recent years, the perioperative mortality rate has decreased significantly. However, the postoperative complication rate is still as high as 20% ~ 60% [1].

Based on a review of the literature by the ISGPF, a postoperative pancreatic fistula (POPF) was defined as an abnormal communication between the pancreatic ductal epithelium and another epithelial surface containing pancreas-derived, enzyme-rich fluid. And the incidence is 3% ~ 45% [2]. If not properly treated, POPF may lead to celiac infection. Celiac infection not only cause but also can aggravate POPF if it is difficult to control. In addition, poor control of pancreatic fistula and celiac infection can also cause considerable complications, such as intra-abdominal bleeding, gastric emptying disorders, sepsis and other complications. These complications are

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
important because they can result in longer hospitalization, increased hospitalization costs and increased mortality [3]. Therefore, it is of great significance to identify reliable parameters that ideally enable effective risk stratification, based on easily available during hospitalization data, in order to adopt strategies tailored to individual situation.

Procalcitonin (PCT), the 116 amino acids long precursor of calcitonin, is abnormally elevated in sepsis. Procalcitonin is regarded as a good diagnostic marker of sepsis in critically ill patients [4]. However the correlation between the level of PCT and the prognosis of POPF is still unclear. So the results of this work may important for extending the knowledge about PCT and its applications as a clinically useful biomarker of infection severity and provide a reference for clinical practice.

**Methods**

**General information**
The clinical data from 67 patients who underwent pancreatectoduodenectomy (PD) and 19 patients who underwent distal pancreatectomy (DP) were prospectively included in this study from January 2017 to December 2018 in hepatobiliary surgery of leshan people's hospital (China) were retrospectively analyzed. All patients were divided into POPF group (grade B pancreatic fistula, grade C pancreatic fistula) and non-POPF group depending on the presence of pancreatic fistula. And fistulas were classified according to the ISGPF classification scheme [2]. Patients meeting the following criteria were excluded in the study: (1) ongoing clinical infections; (2) undergoing emergency surgery; (3) accompanied by rheumatism, rheumatoid and other autoimmune diseases; (4) renal insufficiency (blood creatinine=133 μmol/L); (5) Hepatic Insufficiency (total bilirubin≥200 μmol/L); (6) younger than 18 year.

General information of patients with PD: 43 male patients and 24 female patients; There were 46 cases of pancreatic head carcinoma and 6 cases of benign pancreatic head lesions. There were 7 cases of cholangiocarcinoma and 2 cases of benign bile duct lesions. There were 4 cases of duodenal carcinoma and 2 cases of benign duodenal lesions. General information of DP patients: 4 male patients and 15 female patients; Benign lesions in 8 cases, malignant lesions in 11 cases.

A clinically relevant POPF is defined as a drain output of any measurable volume of fluid with amylase level greater than 3 times the upper Institutional normal serum amylase level, associated with a clinically relevant development/condition related directly to the POPF [2].

Pancreatoduodenectomy (PD) was performed using the standard Whipple reconstruction. The scope of the resection includes the gallbladder, distal common bile duct, pancreatic head, all upper duodenum and jejunum, as well as nearby lymph nodes and fatty connective tissue, and then used Child sequential reconstruction. The corresponding size of the pancreatic duct stenting tube (6–8 Fr) was used as an endoluminal stent between the main pancreatic duct and jejunal lumen. Finally, drainage tubes were routinely placed near the anastomoses of the pancreas and bile bowel [5].

Distal pancreatectomy (DP) was performed with the standard procedure. The pancreatic parenchyma was divided using electrocautery and blade. The main pancreatic duct was ligated with nonabsorbable sutures and the transected pancreas was occluded with interlocking interrupted polypropylene suture (Prolene; Ethicon Products, USA). A drainage tube was routinely placed near the broken end of the pancreas [6].

Preoperative antibiotic prophylaxis consisted of a preoperative dose, an intraoperative dose, and three postoperative doses of Ceftizoxime (3 g intravenous).

**Measurement of biomarkers**
PCT and CRP were compared between POPF and non-POPF groups to explore respective predictive value for pancreatic fistula. Procalcitonin and C-reactive protein were measured in serum samples that were assessed preoperatively and on postoperative days (PODs) 1, 3, 5. Plasma PCT levels were determined using chemiluminescence assay (Triage meterPro, Berlin, Germany). CRP was determined with a turbidimetric assay (Siemens Healthcare Diagnostics). The detection operations were carried out in strict accordance with the kit instructions.

**Ethics statement**
This retrospective study was performed with approval from the Ethics Committee of People’s Hospital of Leshan. A written informed consent from the patients was waived because this study was performed retrospectively.

**Statistical analysis**
Statistical analyses were performed with the Graphpad prism 7.0 and Medcalc statistical software. Analysis of continuous variables was presented as mean ± SD (x ± S) and compared by unpaired t test. The X2 test was used to compare the categorical variables. Mann-whitney test was used to compare the non-normal distribution data. The ROC curve was used to analyze the efficacy of PCT and CRP in POPF prediction after surgery and determine their Cut-off value. The area under the curve (AUC) was calculated and AUC > 0.5 was considered as diagnostic significance. All P values were two sided, and P < 0.05 was considered statistically significant.
Results
Patient demographics and postoperative complications
Between January 2017 and December 2018, a total of 86 consecutive patients were enrolled in this study. There were no statistically significant differences identified in age, gender, BMI, diabetes, abdominal surgery history, preoperative laboratory data, operation time, intraoperative bleeding volume, tumor nature and medical expenses of PD patients between the two groups (P > 0.05).

While the incidence of postoperative hyperglycemia, postoperative ICU rate and postoperative hospital stay were statistically significant (P < 0.05). Postoperative complications occurred in 45 PD patients (67.1%, 45/67). Among them, there were 14 cases (20.8%) of POPF, 31 cases (46.2%) of non-POPF, including 6 cases of incision infection, 6 cases of delayed gastric emptying, 5 cases of heart disease, 4 cases of bile fistula, 4 cases of pulmonary infection, 3 cases of adhesive intestinal obstruction, 3 cases of urinary tract infection, and 1 case of postoperative pancreatitis. Fourteen patients with POPF were cured and discharged after conservative treatment such as anti-infection, nutritional support, irrigation and drainage. The non-POPF patients’ complications improved during hospitalization after treatment and they were discharged smoothly.

For DP patients in the two groups, there were no statistically significant differences in age, gender, BMI, diabetes, abdominal surgery history, preoperative laboratory data, operation time, intraoperative blood loss, postoperative hyperglycemia, tumor character, and Hospitalization expenses. Pancreaticoduodenectomy (PD) remains the standard surgical approach for tumors involving the lower bile duct, the pancreatic head, the duodenal papilla, and the ampulla [7]. This operation is considered risky because of high rates of postoperative mortality and complications. Pancreatic fistula after pancreaticoduodenectomy is a common and serious complication and the most important cause of subsequent complications and death after this procedure. The dilemma of pancreatic fistula after pancreaticoduodenectomy has not yet been resolved [7]. Effective control of pancreatic fistula can reduce the occurrence of hemorrhage and celiac infection [8]. The early prevention and identification of high-risk individuals is a crucial strategy in primary prevention of pancreatic fistula after Pancreaticoduodenectomy (PD). At present, there is still a controversy about whether “pancreatic fistula causes infection” or “celiac infection causes or aggravates pancreatic fistula”. Ven FZ et al. believed that pancreatic juice exuded from the broken edge group on the 1, 3 and 5 days after surgery (P>0.05). DP patients had similar changes in PCT, CRP and WBC levels as PD patients. The results are summarized in Table 2.

Comparison of PCT, CRP, WBC levels during perioperative period
For the PD patients, there was no intergroup difference in PCT, CRP, and WBC between the POPF and non-POPF groups before operation. The PCT level of the POPF group on the 1, 3 and 5 days after surgery was significantly higher than that of the non-POPF group, and the difference was statistically significant (P < 0.05). The CRP level of the POPF group was significantly higher than that of the non-POPF group on the 3rd and 5th day after surgery, with statistically significant difference (P < 0.05). While there was no significant difference in WBC level between the POPF group and the non-POPF
| Characteristics                  | PD       | POPF groups\(n = 14\) | non-POPF groups\(n = 53\) | \(t\) | \(\chi^2\) | \(P\) value | PD       | POPF groups\(n = 5\) | non-POPF groups\(n = 14\) | \(t\) | \(\chi^2\) | \(P\) value |
|----------------------------------|----------|------------------------|-----------------------------|-------|-------|-------------|----------|------------------------|-----------------------------|-------|-------|-------------|
| Age (Year)                       | 58.64 ± 1.74 | 56.49 ± 1.69          | 0.62                        | 0.53  | 53.6 ± 569 | 49.57 ± 322 | 0.63     | 0.53                   | 56.3 ± 1.69 | 51.57 ± 322 | 0.63     | 0.53  |
| Gender (male/female)             | 10/4     | 33/20                  | 0.40                        | 0.52  | 1/4     | 3/11        | 0.004    | 0.94                   | 1/4                        | 3/11   | 0.004 | 0.94        |
| BMI (kg/m²)                      | 22.79 ± 0.84 | 23.25 ± 0.38          | 0.53                        | 0.59  | 22.64 ± 0.71 | 24.65 ± 0.61 | 1.79     | 0.09                   | 22.62 ± 0.71 | 24.65 ± 0.61 | 1.79     | 0.09  |
| Diabetes (n)                     | 3        | 6                      | 0.01                        | 0.90  | 0       | 2           | 0.79     | 0.37                   | 0             | 2      | 0.79  | 0.37        |
| Previous abdominal surgery       | 3        | 16                     | 0.04                        | 0.51  | 3       | 5           | 0.56     | 0.35                   | 3             | 5      | 0.56  | 0.35        |
| Preoperative bilirubin (μmol/L)  | 106.32 ± 0.92 | 1669 ± 1761           | 1.96                        | 0.06  | 12.99 ± 2.89 | 8.85 ± 1.43 | 1.40     | 0.17                   | 12.99 ± 2.89 | 8.85 ± 1.43 | 1.40     | 0.17  |
| Preoperative albumin(g/L)        | 37.07 ± 1.79 | 40.11 ± 0.68          | 1.87                        | 0.06  | 39.6 ± 0.74 | 39.86 ± 0.09 | 0.56     | 0.57                   | 39.6 ± 0.74 | 39.86 ± 0.09 | 0.56     | 0.57  |
| Preoperative hemoglobin(g/L)     | 122.2 ± 4.31 | 1303 ± 224            | 1.64                        | 0.10  | 133.1 ± 3.97 | 118.3 ± 6.64 | 1.28     | 0.21                   | 133.1 ± 3.97 | 118.3 ± 6.64 | 1.28     | 0.21  |
| Operation time (min)             | 242.5 ± 16.04 | 2379 ± 798            | 0.26                        | 0.79  | 190 ± 20.97 | 203.7 ± 14.26 | 0.50     | 0.62                   | 190 ± 20.97 | 203.7 ± 14.26 | 0.50     | 0.62  |
| Intraoperative bleeding (ml)     | 239.2 ± 25.52 | 2435 ± 2012           | 0.10                        | 0.01  | 175.4 ± 28.23 | 134.9 ± 11.1 | 1.63     | 0.12                   | 175.4 ± 28.23 | 134.9 ± 11.1 | 1.63     | 0.12  |
| Postoperative hyperglycemia (n)  | 6        | 7                      | 7.27                        | <0.01 | 1       | 3           | 1.27     | 0.25                   | 1             | 3      | 1.27  | 0.25        |
| Postoperative hypoproteinemia (n)| 5        | 29                     | 0.00                        | 0.92  | 0       | 3           | 1.27     | 0.25                   | 0             | 3      | 1.27  | 0.25        |
| Postoperative ICU admission (n)  | 6        | 10                     | 6.18                        | 0.01  | 4       | 1           | 10.09    | 0.001                  | 4             | 1      | 10.09 | 0.001       |
| Tumor character (benign/malignant)| 4/10     | 6/47                   | 2.59                        | 0.10  | 1/4     | 7/7        | 1.36     | 0.24                   | 1/4           | 7/7    | 1.36  | 0.24        |
| Postoperative hospital stay (d)  | 34.86 ± 3.03 | 22.08 ± 1.27          | 4.37                        | <0.0001 | 22.8 ± 1.42 | 16.29 ± 1.08 | 3.23     | 0.005                  | 22.8 ± 1.42 | 16.29 ± 1.08 | 3.23     | 0.005 |
| Hospitalization cost (RMB ten thousand) | 11.89 ± 1.21 | 10.94 ± 0.62        | 0.69                        | 0.48  | 7.34 ± 0.43 | 6.91 ± 0.50 | 0.47     | 0.64                   | 7.34 ± 0.43 | 6.91 ± 0.50 | 0.47     | 0.64  |
Table 2: Levels (means and standard deviations) of PCT, CRP, and WBC in all patients

| PD                  | Pre-operation | POD1   | POD3   | POD5       | DP                  | Pre-operation | POD1   | POD3   | POD5       |
|---------------------|---------------|--------|--------|------------|---------------------|---------------|--------|--------|------------|
| **PCT (μg/L)**      |               |        |        |            |                     |               |        |        |            |
| POPF groups (n=14)  | 0.20 ± 0.02   | 1.39 ± 0.29* | 1.27 ± 0.18* | 0.66 ± 0.13* | POPF groups (n=5)  | 0.05 ± 0.02   | 1.19 ± 0.23* | 1.19 ± 0.23* | 0.67 ± 0.15* |
| non-POPF groups (n=53) | 0.21 ± 0.01   | 0.55 ± 0.05* | 0.51 ± 0.05* | 0.35 ± 0.03* | non-POPF groups (n=14) | 0.02 ± 0.00   | 0.29 ± 0.07* | 0.29 ± 0.07* | 0.27 ± 0.04* |
| **CRP (mg/L)**      |               |        |        |            |                     |               |        |        |            |
| POPF groups (n=14)  | 12.09 ± 2.57  | 110.8 ± 15.45 | 170.1 ± 34.79* | 102.9 ± 22.07* | POPF groups (n=5)  | 4.73 ± 1.84   | 116.6 ± 5.96 | 129.6 ± 16.22* | 79.11 ± 4.52* |
| non-POPF groups (n=53) | 11.23 ± 1.17  | 109.5 ± 8.04 | 147.4 ± 11.23* | 60.24 ± 7.13* | non-POPF groups (n=14) | 4.35 ± 0.86   | 110.3 ± 2.72 | 85.91 ± 10.18* | 48.21 ± 7.28* |
| **WBC (×10⁹/L)**   |               |        |        |            |                     |               |        |        |            |
| POPF groups (n=14)  | 7.20 ± 1.20   | 13.81 ± 2.46 | 16.16 ± 2.88 | 15.53 ± 1.77 | POPF groups (n=5)  | 4.41 ± 1.72   | 7.19 ± 0.93  | 14.16 ± 3.78  | 15.32 ± 4.97  |
| non-POPF groups (n=53) | 8.00 ± 0.64   | 17.18 ± 1.50 | 10.99 ± 1.21 | 11.43 ± 1.14 | non-POPF groups (n=14) | 3.57 ± 0.67   | 8.43 ± 0.85  | 6.81 ± 0.93   | 12.58 ± 2.61  |

P<0.05"
of the pancreas or leaked from the anastomosis of the pancreatic intestine not only can activate bile and intestinal juice and then corroded the surrounding tissues for digestion, but also can complicated with gastrointestinal pathogens entering the abdominal cavity. Therefore, pancreatic fistula can cause and aggravate celiac infection [9]. However, Ng ZQ et al. believed that bacterial translocation can cause uncontrollable celiac infection leading to rapidly progressing pancreatic fistula which can be fatal if not treated in time [10].

CRP is a polypeptide which is an important marker of inflammation, causes precipitation with C-polysaccharide on the cellular wall of pneumococcus and is responsible for activation of classical complement pathway and increased phagocytosis [11]. CRP, often used as an inflammatory and disease activity marker, is a sensitive marker of non-specific inflammatory response [12]. Surgery can lead to a transient increase in PCT, which can gradually decrease to normal within 48 h without co-infection [12]. Ren et al. demonstrated the value of PCT above 0.98 ng/L on POD 3 and 0.83 ng/L on POD 5 could predict the occurrence of IAI's after definitive operations for intestinal fistulae [13]. Giardino et al. showed that CRP and PCT concentration were associated with an increased risk of developing complications and clinical relevant pancreatic fistula after PD. Use of these biomarkers may help identify those patients at highest risk for perioperative morbidity and can provide a good reference for post-PD management [14]. This study retrospectively analyzed the levels of PCT, CRP, and WBC in 67 patients with PD before and 1 day, 3 days, and 5 days after surgery. The AUC for PCT diagnosis of pancreatic fistula 1 day after surgery was 0.77 (95% CI: 0.675 ~ 0.860). Compared with CRP [0.53 (95% CI: 0.420 ~ 0.639)] and WBC [0.60 (95% CI: 0.490 ~ 0.705)], the optimal cut-off value (cut-off) was 0.67 μg/L. At this time, the sensitivity and specificity of detecting pancreatic fistula were 73.68 and 76.12%, respectively. The results at 3 days after surgery were similar to those at 5 days after surgery. There are several advantages of PCT over CRP. The most striking one, demonstrated in this study, is the enormous range of PCT reactivity resulting in a marked increase in PCT plasma levels, especially after 1,
3 days. On the other hand, PCT concentrations are quite low when pancreatic fistula is present. In contrast, CRP levels are often found to be already increased to higher level. Thus, CRP cannot provide information as to further increases in celiac infection and pancreatic fistula, respectively, since it is already increased to its maximum values during a less severe stage of disease.

Further advantages of PCT are its more rapid kinetics; PCT reacts faster than CRP both during an increase or decrease of inflammation. Therefore, PCT can be used as an effective monitoring index for early prediction of pancreatic fistula after PD.

In addition, in order to effectively eliminate the possibility of PCT elevation during the early postoperative period caused by pancreaticoenteric anastomotic fistula combined with intra-celiac infection caused by enteropathogens. This study introduced 19 patients with distal pancreatectomy (DP). The levels of PCT, CRP and WBC before and after surgery were also analyzed as in the Pancreatoduodenectomy (PD) group. PCT has also proven its value in early detection of simple pancreatic "pancreatic fistula with broken pancreatic margin". Through the comparative analysis of PD and DP patients data. The effect of pancreatic fistula with infection on the specificity value of PCT prediction was indirectly excluded. Therefore, it is further confirmed that PCT is a reliable indicator of POPF's early prediction. So, we recommend that routine detection of PCT level before and after pancreatic surgery (day 1, 3 and 5), which is conducive to early detection of pancreatic fistula and other related complications. This inference needs to be confirmed by relevant studies in other centers. Meanwhile, according to a previous research, age, gender, BMI, diabetes, pancreatic texture, the diameter of main pancreatic duct, abdominal surgery history, intra-abdominal bleeding, blood transfusion, pancreateojejunostomy, nutritional support, somatostatin, hypoproteinemia and other factors might also be related to the risk factor of POPF after PD [15, 16]. The use of PCT alone as an indicator for predicting pancreatic fistula after PD can identify most high-risk patients at an early stage, but there are still a few cases of pancreatic fistula with no significant change in postoperative PCT levels. Therefore, PCT alone as a predictor has some limitations. We recommend that multi-factor and multi-index joint evaluation for pancreatic fistula after PD to improve the accuracy of early prediction.

Conclusions

In conclusion, PCT has early predictive value for the occurrence of pancreatic fistula after PD. Give individualized and accurate postoperative management in time, such as changing antibiotics, adjusting the drainage tube, imaging examination, nutritional support and other measures to prevent the occurrence and development of postoperative complications. However, it has the following limitations: (1) This is a retrospective observational study, and sample size is relatively small due to its being conducted in a single center; (2) use of antibiotic drugs by some patients before inclusion in this study may have altered some biomarkers; (3) we measured PCT and CRP values only once. Therefore, we look forward to improving it in the follow-up work.

Abbreviations

PCT: Procalcitonin; POPF: Pancreatic fistula; PD: Pancreatoduodenectomy; DP: Distal pancreatectomy

Acknowledgments

The authors thank Dr. Yue Chen, who have been a source of encouragement and inspiration. Author Quanyu Zhou express his gratitude to his wife for her warm support by this paper.

Authors' contributions

Protocol/project development: Z.-H.L. Data acquisition and interpretation of data: Q.-Y.Z. Statistics analysis of data: Q.-Y.Z and Y.-X.X. Manuscript drafting: Q.-Y.Z and Y.-X.X. Manuscript Revision and accountable for all aspects of the study: Q.-Y.Z. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request (Email: lei1tseha@126.com).

Ethics approval and consent to participate

This retrospective study was performed with approval from the Ethics Committee of People's Hospital of Leshan. A written informed consent from the patients was waived because this study was performed retrospectively.

Consent for publication

Not applicable.

Competing interests

The author(s) declare that they have no competing interests.

Author details

1 Department of Hepatobiliary and Pancreatic Surgery, The People's Hospital of Leshan City, Leshan, Sichuan 614000, People's Republic of China.
2 Department of Nuclear Medicine, The Affiliated Hospital, Southwest Medical University, No 15 TaiPing St, Jiangyang District, Luzhou 64600, Sichuan, People's Republic of China.

Received: 7 March 2020 Accepted: 22 April 2020

Published online: 06 May 2020

References

1. Benjamin M, Lydia G, Andrea M, Arnaud A, Jean L. Pancreatecogastrostomy is superior to pancreateojejunostomy for prevention of pancreatic fistula after pancreatoduodenectomy: an updated meta-analysis of randomized controlled trials. Ann Surg. 2015;261(5):882–7.
2. Bassi C, Marchegiani G, Derenlis C, Sarr M, Abu HM, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.
3. Wente MN, Claudio B, Christos D, Abe F, Gouma DJ, Izibicki JR, Neoptolemos JP, Padbury RT, Sarr MG, L. William T. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the international study Group of Pancreatic Surgery (ISGPS). Surgery 2007, 142(5):761–769.
4. Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, Biswas A, Sood S, Goel M, Das M, et al. Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes. 2014;7:458.
5. Are C, Dhir M, Ravipati L. History of pancreaticoduodenectomy: early misconceptions, initial milestones and the pioneers. HPB (Oxford). 2011;13(6):377–84.

6. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63(5):318–48.

7. Hu BY, Wan T, Zhang WZ, Dong JH. Risk factors for postoperative pancreatic fistula: analysis of 539 successive cases of pancreaticoduodenectomy. World J Gastroenterol. 2016;22(34):7797–805.

8. Shrikhande SV, Sivasanker M, Vollmer CM, Fries H, Besselink MG, Fingerhut A, Yeo CJ, Fernandez-Delcastillo C, Dervenis C, Halloran C. Pancreatic anastomosis after pancreatoduodenectomy: a position statement by the international study Group of Pancreatic Surgery (ISGPS). Surgery. 2017;161(5):1221.

9. Ven FZ, Correa-Gallego C, Ferrone CR, Veillette GR, Warshaw AL, Lillemoe KD, Fernandez-del CC. Early drain removal—the middle ground between the drain versus no drain debate in patients undergoing Pancreatoduodenectomy: a prospective validation study. Ann Surg. 2015;262(2):378–83.

10. Ng QZ, Suthananthan AE, Rao S. Effect of preoperative biliary stenting on post-operative infectious complications in pancreaticoduodenectomy. Ann Hepatobiliary Pancreat Surg. 2017;21(4):212–6.

11. Golak A, Yilmaz C, Toprak B, Aktogu S. Procalcitonin and CRP as biomarkers in discrimination of community-acquired pneumonia and exacerbation of COPD. J Med Biochem. 2017;36(2):122–6.

12. Shu XL, Yu TT, Kang K, Zhao J. Effects of glutamine on markers of intestinal inflammatory response and mucosal permeability in abdominal surgery patients: a meta-analysis. Exp Ther Med. 2016;12(6):3499–506.

13. Ren H, Ren J, Hu Q, Wang G, Gu G, Li G, Wu X, Hong Z, Li J. Prediction of procalcitonin for postoperative intracalicia infections after definitive operation of intestinal fistulae. J Surg Res. 2016;206(2):280–5.

14. Giardino A, Spolverato G, Regi P, Frigerio I, Scopelliti F, Gieli R, Pawlik Z, Pederzoli P, Bassi C, Butturini G. C-reactive protein and Procalcitonin as predictors of postoperative inflammatory complications after pancreatic surgery. J Gastrointest Surg. 2016;20(8):1482–92.

15. Schindl M, Fugger R, Gotzinger P, Langle F, Zitt M, Stattnner S, Komprat P, Sahora K, Hauschek D, Grant M. Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy. Br J Surg. 2018;105(7):811–9.

16. Callery MP, Pratt WB, Kent TS, ChaiKof EL, Vollmer CJ. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013;216(1):1–14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.